Novartis

Novartis increases growth potential through integration of Alcon

Alcon is innovative new growth platform with leading position in eye care segment.

Novartis | 13 September 2011

• Novartis

Novartis drug Afinitor gains EU approval

Novartis announced that the European Commission has approved Afinitor (everolimus) tablets for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors (NET) of pancreatic origin in adults with progressive…

Novartis | 05 September 2011

Novartis International BioCamp spotlights diversity

Novartis has opened its eighth annual International Biotechnology Leadership Camp (BioCamp), a three-day seminar bringing biotechnology and business experts together with 60 selected students from leading international universities in 24 countries an…

Novartis | 29 August 2011

Phase 3 trial of Novartis drug Afinitor met primary endpoint

Novartis announced phase 3 trial results that showed more than one-third of patients taking Afinitor (everolimus) tablets experienced a 50 percent or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous b…

Novartis | 08 July 2011

Novartis receives approval in Japan for Onbrez inhalation capsules

Novartis announced that it has received regulatory approval in Japan for Onbrez inhalation capsules (indacaterol) 150 mcg once-daily for the treatment of chronic obstructive pulmonary disease (COPD). Onbrez is said to be the only once-daily COPD ther…

Novartis | 01 July 2011

FDA endorses efficacy but not safety of Novartis drug for gouty arthritis

An advisory committee of the Food and Drug Administration (FDA) has voted in favor of the overall efficacy but not the overall safety of ACZ885 (canakinumab) to treat gouty arthritis attacks in patients who cannot obtain adequate relief with non-ster…

Novartis | 22 June 2011

Novartis application for expanded Menveo indication accepted for FDA review

Novartis announced that the US FDA has accepted for review its supplemental Biologics License Application (sBLA) to expand the Menveo (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) indication to include…

Novartis | 16 June 2011

Novartis supports influenza framework at World Health Assembly

Novartis welcomes the decision to endorse the Pandemic Influenza Preparedness Framework (PIP Framework) at the sixty-fourth World Health Assembly. The PIP Framework sets out the roles and commitments of different stakeholders, including the World Hea…

Novartis | 19 May 2011